相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
Bin Fan et al.
INVESTIGATIONAL NEW DRUGS (2020)
Blockade of Glutathione Metabolism in IDH1-Mutated Glioma
Xiaoying Tang et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma
Zenon Konteatis et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Sue Han et al.
BRITISH JOURNAL OF CANCER (2020)
Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
Di Yu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
Yuxiang Wang et al.
SCIENCE ADVANCES (2020)
Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma
Ingo K. Mellinghoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Oncometabolites suppress DNA repair by disrupting local chromatin signalling
Parker L. Sulkowski et al.
NATURE (2020)
PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas
Imran Noorani et al.
GENOME BIOLOGY (2020)
Targeting IDH1-Mutated Malignancies with NRF2 Blockade
Yang Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
Felipe J. Nunez et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre
Zane Jaunmuktane et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Brusatol, an NRF2 inhibitor for future cancer therapeutic
Sabrina J. Cai et al.
CELL AND BIOSCIENCE (2019)
Genetically Engineered Mouse Models of Gliomas: Technological Developments for Translational Discoveries
Imran Noorani
CANCERS (2019)
Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation
Cheila Brito et al.
BMC CANCER (2019)
Molecular basis for the function of the ?? heterodimer of human NAD-dependent isocitrate dehydrogenase
Pengkai Sun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
The current state of immunotherapy for gliomas: an eye toward the future
Peter E. Fecci et al.
JOURNAL OF NEUROSURGERY (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence
Sevin Turcan et al.
NATURE GENETICS (2018)
IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
Remco J. Molenaar et al.
CLINICAL CANCER RESEARCH (2018)
Cancer-associated 2-oxoglutarate analogues modify histone methylation by inhibiting histone lysine demethylases
Tuomas Laukka et al.
JOURNAL OF MOLECULAR BIOLOGY (2018)
Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair
Parker L. Sulkowski et al.
NATURE GENETICS (2018)
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Lukas Bunse et al.
NATURE MEDICINE (2018)
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
Yanxin Lu et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress
Susan J. Gelman et al.
CELL REPORTS (2018)
A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence
Camila Ferreira de Souza et al.
CELL REPORTS (2018)
Mutant IDH1 Promotes Glioma Formation In Vivo
Beatrice Philip et al.
CELL REPORTS (2018)
Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma
Samuel K. McBrayer et al.
CELL (2018)
Mechanisms of DNA Damage, Repair, and Mutagenesis
Nimrat Chatterjee et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2017)
Epileptic features and survival in glioblastomas presenting with seizures
Manuel Toledo et al.
EPILEPSY RESEARCH (2017)
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomase
Gary Kohanbash et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
A. Chaturvedi et al.
LEUKEMIA (2017)
Vaccine-based immunotherapeutic approaches to gliomas and beyond
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2017)
Mutant IDH1 and seizures in patients with glioma
Hao Chen et al.
NEUROLOGY (2017)
Glioma Subclassifications and Their Clinical Significance
Ricky Chen et al.
NEUROTHERAPEUTICS (2017)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Epigenetic therapy with inhibitors of histone methylation suppresses DNA damage signaling and increases glioma cell radiosensitivity
Ozge Gursoy-Yuzugullu et al.
ONCOTARGET (2017)
Oncometabolite D-2-Hydroxyglutarate enhances gene silencing through inhibition of specific H3K36 histone demethylases
Ryan Janke et al.
eLife (2017)
The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity
Kensuke Tateishi et al.
CANCER RESEARCH (2017)
Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Yanxin Lu et al.
CANCER RESEARCH (2017)
Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Stefan Pusch et al.
ACTA NEUROPATHOLOGICA (2017)
Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
Uzay E. Emir et al.
CANCER RESEARCH (2016)
Insulator dysfunction and oncogene activation in IDH mutant gliomas
William A. Flavahan et al.
NATURE (2016)
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
Macarena I. de la Fuente et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2
Satoshi Inoue et al.
CANCER CELL (2016)
Expression of Idh1R132H in the Murine Subventricular Zone Stem Cell Niche Recapitulates Features of Early Gliomagenesis
Chiara Bardella et al.
CANCER CELL (2016)
An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy
Yuan Yang et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2016)
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Tor-Christian Aase Johannessen et al.
MOLECULAR CANCER RESEARCH (2016)
On the Utility of Short Echo Time (TE) Single Voxel 1H-MRS in Non-Invasive Detection of 2-Hydroxyglutarate (2HG); Challenges and Potential Improvement Illustrated with Animal Models Using MRUI and LCModel
Hwon Heo et al.
PLOS ONE (2016)
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes
Polina Matre et al.
ONCOTARGET (2016)
Extreme Vulnerability of IDH1 Mutant Cancers to NAD plus Depletion
Kensuke Tateishi et al.
CANCER CELL (2015)
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
Remco J. Molenaar et al.
CANCER RESEARCH (2015)
Mutational landscape and clonal architecture in grade II and III gliomas
Hiromichi Suzuki et al.
NATURE GENETICS (2015)
Immunomodulation: checkpoint blockade etc.
William T. Curry et al.
NEURO-ONCOLOGY (2015)
Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents
Pu Wang et al.
CELL REPORTS (2015)
Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
Jinlong Shi et al.
TUMOR BIOLOGY (2015)
Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance
Shigeo Ohba et al.
CANCER RESEARCH (2014)
IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism
Alexandra R. Grassian et al.
CANCER RESEARCH (2014)
IDH1 mutation is associated with seizures and protoplasmic subtype in patients with low-grade gliomas
Simon V. Liubinas et al.
EPILEPSIA (2014)
Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations
Ashkan Emadi et al.
EXPERIMENTAL HEMATOLOGY (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Characterization of metabolites in infiltrating gliomas using ex vivo 1H high- resolution magic angle spinning spectroscopy
Adam Elkhaled et al.
NMR IN BIOMEDICINE (2014)
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Fumiharu Ohka et al.
TUMOR BIOLOGY (2014)
A High-Throughput Fluorimetric Assay for 2-Hydroxyglutarate Identifies Zaprinast as a Glutaminase Inhibitor
Adnan Elhammali et al.
CANCER DISCOVERY (2014)
The genetic landscape of anaplastic astrocytoma
Patrick J. Killela et al.
ONCOTARGET (2014)
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas
Patrick J. Killela et al.
ONCOTARGET (2014)
Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy
Manabu Natsumeda et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2014)
Mutant IDH1 Enhances the Production of 2-Hydroxyglutarate Due to Its Kinetic Mechanism
Alan R. Rendina et al.
BIOCHEMISTRY (2013)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Seizure characteristics and prognostic factors of gliomas
Melissa Kerkhof et al.
EPILEPSIA (2013)
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
Julie-Aurore Losman et al.
GENES & DEVELOPMENT (2013)
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Ovidiu C. Andronesi et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
A comparative study of short- and long-TE 1H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors
Changho Choi et al.
NMR IN BIOMEDICINE (2013)
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
Patrick J. Killela et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells
Dan Rohle et al.
SCIENCE (2013)
Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
Fang Wang et al.
SCIENCE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Dopamine protects neurons against glutamate-induced excitotoxicity
A. Vaarmann et al.
CELL DEATH & DISEASE (2013)
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft
Alexandra Borodovsky et al.
ONCOTARGET (2013)
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Sevin Turcan et al.
ONCOTARGET (2013)
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
Felix Sahm et al.
ACTA NEUROPATHOLOGICA (2012)
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
Whitney B. Pope et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Chao Lu et al.
NATURE (2012)
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Sevin Turcan et al.
NATURE (2012)
2-hydroxyglutarate detection by magnetic resonance spectroscopy in subjects with IDH-mutated gliomas
Changho Choi et al.
NATURE MEDICINE (2012)
Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation
Jelena Lazovic et al.
NEURO-ONCOLOGY (2012)
Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Darrell R. Borger et al.
ONCOLOGIST (2012)
Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
Ovidiu C. Andronesi et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom
Florian Stockhammer et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2012)
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo
Janeta Popovici-Muller et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Yuchen Jiao et al.
ONCOTARGET (2012)
DNA repair dysregulation from cancer driver to therapeutic target
Nicola J. Curtin
NATURE REVIEWS CANCER (2012)
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Tatsuhiro Shibata et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
Wei Xu et al.
CANCER CELL (2011)
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
Christian Hartmann et al.
CLINICAL CANCER RESEARCH (2011)
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Rasheduzzaman Chowdhury et al.
EMBO REPORTS (2011)
Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications
Sophie E. Polo et al.
GENES & DEVELOPMENT (2011)
Molecular signatures classify astrocytic gliomas by IDH1 mutation status
Grischa Toedt et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours
M. Fernanda Amary et al.
JOURNAL OF PATHOLOGY (2011)
DNA Methylation, Isocitrate Dehydrogenase Mutation, and Survival in Glioma
Brock C. Christensen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Metabolism unhinged: IDH mutations in cancer
John R. Prensner et al.
NATURE MEDICINE (2011)
2-Hydroxyglutarate Production, but Not Dominant Negative Function, Is Conferred by Glioma-Derived NADP+-Dependent Isocitrate Dehydrogenase Mutations
Genglin Jin et al.
PLOS ONE (2011)
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Zachary J. Reitman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Chetan Bettegowda et al.
SCIENCE (2011)
Extracellular glutamate: functional compartments operate in different concentration ranges
Khaled Moussawi et al.
FRONTIERS IN SYSTEMS NEUROSCIENCE (2011)
Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
Christian Hartmann et al.
ACTA NEUROPATHOLOGICA (2010)
Molecular diagnostics of gliomas: state of the art
Markus J. Riemenschneider et al.
ACTA NEUROPATHOLOGICA (2010)
IDH1R132 mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain
Giselle Y. Lopez et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Houtan Noushmehr et al.
CANCER CELL (2010)
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Maria E. Figueroa et al.
CANCER CELL (2010)
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Meghan J. Seltzer et al.
CANCER RESEARCH (2010)
IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group
Martin J. van den Bent et al.
CLINICAL CANCER RESEARCH (2010)
IDH1 and IDH2 Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal Tandem Duplication
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (vol 462, pg 739, 2010)
Lenny Dang et al.
NATURE (2010)
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
C. Houillier et al.
NEUROLOGY (2010)
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
M. Labussiere et al.
NEUROLOGY (2010)
IDH mutations in glioma and acute myeloid leukemia
Lenny Dang et al.
TRENDS IN MOLECULAR MEDICINE (2010)
Mutant Metabolic Enzymes Are at the Origin of Gliomas
Hai Yan et al.
CANCER RESEARCH (2009)
IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Sumihito Nobusawa et al.
CLINICAL CANCER RESEARCH (2009)
Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
Michael Weller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Marc Sanson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas Clinical article
Kaisorn L. Chaichana et al.
JOURNAL OF NEUROSURGERY (2009)
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Elaine R. Mardis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Analysis of the IDH1 codon 132 mutation in brain tumors
Joerg Balss et al.
ACTA NEUROPATHOLOGICA (2008)
Seizure characteristics and control following resection in 332 patients with low-grade gliomas
Edward F. Chang et al.
JOURNAL OF NEUROSURGERY (2008)
An integrated genomic analysis of human glioblastoma Multiforme
D. Williams Parsons et al.
SCIENCE (2008)
Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management
Melanie S. M. van Breemen et al.
LANCET NEUROLOGY (2007)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity
X Xu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Epilepsy in low-grade gliomas:: The impact on cognitive function and quality of life
M Klein et al.
ANNALS OF NEUROLOGY (2003)
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents
M Esteller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
